HPV vaccination plays an important role in reducing HPV-associated cancers. Male 4vHPV series completion was low (24.3%) despite ACIP routine use recommendation. Completion was greater in younger boys (11–12 years) than older boys (13–17 years). Early initiation and identification of a primary care provider may improve 4vHPV series completion.